MGTX - MeiraGTx Holdings plc
IEX Last Trade
6.145
0.035 0.570%
Share volume: 17,201
Last Updated: Thu 26 Dec 2024 08:29:55 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$6.11
0.03
0.57%
Fundamental analysis
6%
Profitability
0%
Dept financing
16%
Liquidity
44%
Performance
0%
Performance
5 Days
1.31%
1 Month
-3.44%
3 Months
47.61%
6 Months
46.56%
1 Year
-13.71%
2 Year
2.66%
Key data
Stock price
$6.14
DAY RANGE
$5.96 - $6.17
52 WEEK RANGE
$3.99 - $7.57
52 WEEK CHANGE
-$13.34
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
Company detail
CEO: Alexandria Forbes
Region: US
Website: meiragtx.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: meiragtx.com
Employees: 300
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
MeiraGTx Holdings plc focuses on developing treatments for patients with serious diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop a gene therapy treatment using the company's proprietary riboswitch technology.
Recent news